Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin J Marchbank

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Annals of Translational Medicine|January 8, 2019
Targeting properdin in the treatment of atypical haemolytic uraemic syndrome: better than eculizumab?Kate Smith-Jackson, Kevin J Marchbank
Immunobiology|August 22, 2023
XXIX International Complement Workshop Newcastle 2023Kevin J Marchbank, David Kavanagh, Claire L Harris
Immunological Reviews|October 7, 2022
Contribution of animal models to the mechanistic understanding of Alternative Pathway and Amplification Loop (AP/AL)-driven Complement-mediated DiseasesBeth G Gibson, Thomas E Cox, Kevin J Marchbank
Journal of Immunology (Baltimore, Md. : 1950)|May 21, 2005
B cells from mice prematurely expressing human complement receptor type 2 are unresponsive to T-dependent antigensLouise Birrell, Liudmila Kulik, B Paul Morgan, et al.
Frontiers in Immunology|October 12, 2020
Editorial: Autoantibodies in Kidney DiseasesKevin J Marchbank, Ashley Frazer-Abel, Marie-Agnes Dragon-Durey, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 24, 2002
Expression of human complement receptor type 2 (CD21) in mice during early B cell development results in a reduction in mature B cells and hypogammaglobulinemiaKevin J Marchbank, Liudmila Kulik, Matthew G Gipson, et al.
Oncotarget|October 10, 2015
A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLLEva-Maria Nichols, Rachel Jones, Rachael Watson, et al.
Immunology Letters|March 9, 2005
Complement: central to innate immunity and bridging to adaptive responsesB Paul Morgan, Kevin J Marchbank, M Paula Longhi, et al.
Immunobiology|July 26, 2011
Mice expressing human CR1/CD35 have an enhanced humoral immune response to T-dependent antigens but fail to correct the effect of premature human CR2 expressionIsabel Y Pappworth, Christine Hayes, Jason Dimmick, et al.
Molecular Immunology|February 4, 2009
Increased B cell deletion and significantly reduced auto-antibody titre due to premature expression of human complement receptor 2 (CR2, CD21)Isabel Y Pappworth, Liudmila Kulik, Catherine Haluszczak, et al.
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Annals of Translational Medicine|January 8, 2019
Targeting properdin in the treatment of atypical haemolytic uraemic syndrome: better than eculizumab?Kate Smith-Jackson, Kevin J Marchbank
Immunobiology|August 22, 2023
XXIX International Complement Workshop Newcastle 2023Kevin J Marchbank, David Kavanagh, Claire L Harris
Immunological Reviews|October 7, 2022
Contribution of animal models to the mechanistic understanding of Alternative Pathway and Amplification Loop (AP/AL)-driven Complement-mediated DiseasesBeth G Gibson, Thomas E Cox, Kevin J Marchbank
Journal of Immunology (Baltimore, Md. : 1950)|May 21, 2005
B cells from mice prematurely expressing human complement receptor type 2 are unresponsive to T-dependent antigensLouise Birrell, Liudmila Kulik, B Paul Morgan, et al.
Frontiers in Immunology|October 12, 2020
Editorial: Autoantibodies in Kidney DiseasesKevin J Marchbank, Ashley Frazer-Abel, Marie-Agnes Dragon-Durey, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 24, 2002
Expression of human complement receptor type 2 (CD21) in mice during early B cell development results in a reduction in mature B cells and hypogammaglobulinemiaKevin J Marchbank, Liudmila Kulik, Matthew G Gipson, et al.
Oncotarget|October 10, 2015
A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLLEva-Maria Nichols, Rachel Jones, Rachael Watson, et al.
Immunology Letters|March 9, 2005
Complement: central to innate immunity and bridging to adaptive responsesB Paul Morgan, Kevin J Marchbank, M Paula Longhi, et al.
Immunobiology|July 26, 2011
Mice expressing human CR1/CD35 have an enhanced humoral immune response to T-dependent antigens but fail to correct the effect of premature human CR2 expressionIsabel Y Pappworth, Christine Hayes, Jason Dimmick, et al.
Molecular Immunology|February 4, 2009
Increased B cell deletion and significantly reduced auto-antibody titre due to premature expression of human complement receptor 2 (CR2, CD21)Isabel Y Pappworth, Liudmila Kulik, Catherine Haluszczak, et al.
Pageof 6